Join
Search

New Allegations of Political and Corporate Pressure on FDA

Bookmark and Share

In today’s New York Times, Gardiner Harris describes tensions between the FDA, Congress and the White House regarding the agency’s attempts to inform and protect the public. It’s an incredible article that helps demonstrate the pervasiveness of both political and corporate pressure on the agency, and how those who do not have scientific training in public health attempt to take decision-making authority on what should be scientific issues away from those who do.

Last Thursday, UCS released an analysis showing that drug, medical device, and biotech companies have spent $700 million in recent years lobbying Congress and the executive branch, hundreds of millions more than the oil and gas industry and the insurance industry. Also, in a recent UCS survey, hundreds of FDA scientists reported political and corporate attempts to influence their work.

Senior White House official Cass Sunstein

Senior White House official Cass Sunstien (pictured above) pressured the FDA to delay a ban on the asthma inhaler Primatine Mist. Members of Congress also tried to intervene by writing FDA officials and even introducing legislation to prevent the agency from acting, according to the New York Times. Photo: U.S. Senate

The article considers commercial pressure in the case of the asthma inhaler Primatine Mist. Mr. Harris writes:

“The F.D.A. and the White House disagreed over whether to remove from the market the asthma medicine Primatene Mist because it contained chlorofluorocarbons or CFCs, banned by international treaty because they have been found to deplete the earth’s ozone layer. The F.D.A. had for years warned Primatene’s maker of the impending ban, but the company had not followed other inhaler makers and created a product that did not use CFCs even after an additional year’s reprieve.

Amphastar, Primatene’s maker, underwrote an expensive lobbying campaign to stop the F.D.A.’s planned ban. More than a dozen members of the House signed a letter to the Obama administration asking for an extension of the deadline. Senators Pat Roberts of Kansas and Jim DeMint of South Carolina, both Republicans, introduced legislation that would have barred the F.D.A. from removing Primatene from the market because they said the ban was a burdensome regulation.

The reporter goes on to describe that Cass Sunstein, a senior official at the White House Office of Management and Budget, also got involved:

Such lobbying is not unusual for the F.D.A. What was unusual, several top agency officials said, was the effort by Mr. Sunstein to persuade the agency to give Primatene a reprieve. “Usually, we can ignore all the lobbying stuff. We get it all the time,” a top F.D.A. official said. “But when we get pressure from inside the administration, that’s when it gets really tough.”

Mr. Sunstein must approve new government rules. But in the case of Primatene, the law and rules were already in effect. The F.D.A. did not need his agreement and resisted his entreaties, officials said.

The $700 million in lobbying is paying off as Congress considers giving companies more influence over how the FDA approves drugs and medical devices by allowing more scientists paid by the drug companies to sit on FDA scientific advisory panels that evaluate new products for safety and effectiveness.

UCS is tracking these congressional efforts and making the case for stronger conflict of interest standards at the agency.

We’re also encouraging people to weigh in with personal stories of how drugs and devices have affected them—in both positive and negative ways.  As my colleague Celia Wexler said, a voter can outweigh a dollar, even in these cynical times.

Posted in: Scientific Integrity Tags: , , , , ,

About the author: Michael Halpern is an expert on political interference in science and solutions to reduce suppression, manipulation, and distortion of government science. See Michael's full bio.

Support from UCS members make work like this possible. Will you join us? Help UCS advance independent science for a healthy environment and a safer world.

  • Mahin Sadrai

    Why doesn’t the UCS and EPA join affords and have the company to provide documents that their FCC,s products are not polluting the air?
    I thought this was an established correlation between FCC,s and the ozone layer?

  • Chris browning

    The only way to stop this is to get corporate money out of politics. Sadly we are moving in the opposite direction. These companies think they are above the law. They agree to conditions and then pressure the government to give them exemptions and then accuse the government of stifling the economy when the government stands up to them. It all does the public a great disservice and won’t stop until corporate power is held in check.

Comment Policy

UCS welcomes comments that foster civil conversation and debate. To help maintain a healthy, respectful discussion, please focus comments on the issues, topics, and facts at hand, and refrain from personal attacks. Posts that are commercial, obscene, rude or disruptive will be removed.

Please note that comments are open for two weeks following each blog post. When commenting, you must use your real name. Valid email addresses are required. (UCS respects your privacy; we will not display, lend, or sell your email address for any reason.)